PLoS One:急性缺血性卒中患者,入院体温与三天后闭塞血管再通没有关系

2015-10-29 phylis 译 MedSci原创

背景:闭塞颅内动脉再通受到温度依赖酶的影响,包括阿替普酶。研究者评估入院体温和再通之间的关系。方法:共有13个中心278名急性缺血性卒中症状开始9个小时内的患者,研究者对其进行入院CT血管造影检查。研究者计算入院体温每升高1摄氏度和三天内再通的关系。结果:80%闭塞动脉发生再通。校正年龄,入院NIHSS分数及阿替普酶治疗后,入院体温和三天再通没有关系()。应用阿替普酶治疗与未治疗的患者结果一致。结

背景:闭塞颅内动脉再通受到温度依赖酶的影响,包括阿替普酶。研究者评估入院体温和再通之间的关系。

方法:共有13个中心278名急性缺血性卒中症状开始9个小时内的患者,研究者对其进行入院CT血管造影检查。研究者计算入院体温每升高1摄氏度和三天内再通的关系。

结果:80%闭塞动脉发生再通。校正年龄、入院NIHSS分数及阿替普酶治疗后,入院体温和三天再通没有关系(每0.1°摄氏度调整后的优势比,0.99;95%置信区间,0.94 - -1.05,p = 0.70)。应用阿替普酶治疗与未治疗的患者结果一致。

结论:研究结果表明:不管是否应用阿替普酶治疗,急性缺血性卒中患者入院体温和闭塞颅内动脉三天后再通没有关系。

原文出处:

Geurts M, van der Worp HB, Horsch AD,et al. No Relation between Body Temperature and Arterial Recanalization at Three Days in Patients with Acute Ischaemic Stroke. PLoS One. 2015,Oct 16


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1789722, encodeId=63571e8972244, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Tue Jun 07 08:26:00 CST 2016, time=2016-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892693, encodeId=58381892693f7, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Tue Apr 26 16:26:00 CST 2016, time=2016-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806043, encodeId=358518060438e, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Thu Dec 10 18:26:00 CST 2015, time=2015-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2010334, encodeId=d016201033481, content=<a href='/topic/show?id=9cf7e9360d2' target=_blank style='color:#2F92EE;'>#缺血性卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79360, encryptionId=9cf7e9360d2, topicName=缺血性卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1072181, createdName=wjywjy, createdTime=Tue Dec 15 07:26:00 CST 2015, time=2015-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720071, encodeId=5a4e1e20071a9, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Thu May 26 17:26:00 CST 2016, time=2016-05-26, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1789722, encodeId=63571e8972244, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Tue Jun 07 08:26:00 CST 2016, time=2016-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892693, encodeId=58381892693f7, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Tue Apr 26 16:26:00 CST 2016, time=2016-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806043, encodeId=358518060438e, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Thu Dec 10 18:26:00 CST 2015, time=2015-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2010334, encodeId=d016201033481, content=<a href='/topic/show?id=9cf7e9360d2' target=_blank style='color:#2F92EE;'>#缺血性卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79360, encryptionId=9cf7e9360d2, topicName=缺血性卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1072181, createdName=wjywjy, createdTime=Tue Dec 15 07:26:00 CST 2015, time=2015-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720071, encodeId=5a4e1e20071a9, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Thu May 26 17:26:00 CST 2016, time=2016-05-26, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1789722, encodeId=63571e8972244, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Tue Jun 07 08:26:00 CST 2016, time=2016-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892693, encodeId=58381892693f7, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Tue Apr 26 16:26:00 CST 2016, time=2016-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806043, encodeId=358518060438e, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Thu Dec 10 18:26:00 CST 2015, time=2015-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2010334, encodeId=d016201033481, content=<a href='/topic/show?id=9cf7e9360d2' target=_blank style='color:#2F92EE;'>#缺血性卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79360, encryptionId=9cf7e9360d2, topicName=缺血性卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1072181, createdName=wjywjy, createdTime=Tue Dec 15 07:26:00 CST 2015, time=2015-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720071, encodeId=5a4e1e20071a9, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Thu May 26 17:26:00 CST 2016, time=2016-05-26, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1789722, encodeId=63571e8972244, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Tue Jun 07 08:26:00 CST 2016, time=2016-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892693, encodeId=58381892693f7, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Tue Apr 26 16:26:00 CST 2016, time=2016-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806043, encodeId=358518060438e, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Thu Dec 10 18:26:00 CST 2015, time=2015-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2010334, encodeId=d016201033481, content=<a href='/topic/show?id=9cf7e9360d2' target=_blank style='color:#2F92EE;'>#缺血性卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79360, encryptionId=9cf7e9360d2, topicName=缺血性卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1072181, createdName=wjywjy, createdTime=Tue Dec 15 07:26:00 CST 2015, time=2015-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720071, encodeId=5a4e1e20071a9, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Thu May 26 17:26:00 CST 2016, time=2016-05-26, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1789722, encodeId=63571e8972244, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Tue Jun 07 08:26:00 CST 2016, time=2016-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892693, encodeId=58381892693f7, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Tue Apr 26 16:26:00 CST 2016, time=2016-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806043, encodeId=358518060438e, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Thu Dec 10 18:26:00 CST 2015, time=2015-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2010334, encodeId=d016201033481, content=<a href='/topic/show?id=9cf7e9360d2' target=_blank style='color:#2F92EE;'>#缺血性卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79360, encryptionId=9cf7e9360d2, topicName=缺血性卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1072181, createdName=wjywjy, createdTime=Tue Dec 15 07:26:00 CST 2015, time=2015-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720071, encodeId=5a4e1e20071a9, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Thu May 26 17:26:00 CST 2016, time=2016-05-26, status=1, ipAttribution=)]

相关资讯

Neurotox Res:缺血性卒中患者尿酸的预测价值

心血管疾病或卒中患者中,血清尿酸(UA)的重要性和功能尚不清楚。研究人员旨在评估卒中患者的UA水平以及内源性UA与急性缺血性卒中(AIS)患者临床预后的相关性,尤其是性别和UA水平与AIS预后可能的关系。研究人员筛选了缺血性卒中48h内的患者303名,101名患者进行了溶栓治疗。入院后第二天清晨测量血清UA(μmol/L)。患者预后用发病后90天mRS评估。根据血清UA水平,将患者分为四组。应用二

Cerebrovasc Dis: 无症状性实质出血史患者,静脉溶栓后脑内出血的风险未增加

背景:NINDS试验显示静脉给予rtPA能够改善急性缺血性卒中的神经功能预后。排除了脑内出血(ICH)史的患者,可能是基于这类患者出血的风险增加。然而,是否应反对或支持给予先前存在ICH的患者静脉rtPA溶栓,尚不清楚。研究人员旨在通过一项回顾性基于医院单中心研究确定给予这种患者静脉rtPA溶栓的安全性。方法:研究人员总数了2006年1月到2014年4月间医院卒中中心接受静脉rtPA治疗的所有患者

PLoS One: 评估急性缺血性卒中患者非工作日时间急诊治疗

背景和目的:非工作日时间急性缺血性卒中患者的急诊处理的质量是有争议的。因此,研究人员旨在分析在非工作日时间入院的患者性能指标,治疗治疗以及临床预后。 方法:研究选取了2007年9月到2008年8月在中国国家卒中登记(CNSR)的缺血性卒中患者,共4493名。正常工作日指周一到周五上午8点到下午5点到达急诊部的患者。非工作日时间包括工作日时间剩余事件以及法定假期。运动多变量logistic回归模型分

Neurosurgery:颈动脉夹层患者可进行血管内治疗

背景:颈动脉夹层(CAD)的患者发生急性缺血性卒中(AIS)后血管内治疗的安全和可行性尚不清楚。目的:报道研究者CAD发生AIS患者进行干预措施,并通过系统性综述CAD的静脉溶栓(IVT)等传统治疗和CAD发生AIS的干预措施相比较。方法:回顾性分析来自两个第三中心的狭窄闭塞的CAD患者,患者NIHSS分数>5并且症状持续<12小时。搜索PubMed数据库系统综述CAD患者的进行IVT

Cerebrovasc Dis:“卒中房”有助于急性缺血性卒中患者治疗

背景:对于急性缺血性卒中患者,血管内治疗(IAT)被认为是清除结构性斑块的有效措施。因为患者预后主要依赖于治疗的时间(时间就是大脑),研究者评估在动脉内卒中治疗之前,基于时间敏感性(诊断和治疗在一个地方)干预的效果。方法:评估2010年4月26号前后进行IAT的大血管闭塞的急性卒中患者,这些患者诊断和治疗过程都在同一个地方(“卒中房”)。结果:进行干预后,174名患者入院到血管造影的时间显著缩短(

J Am Heart Assoc:高血糖与急性缺血性卒中溶栓后预后的关系

背景:高血糖与急性缺血性卒中(AIS)的不良预后相关,并且可能影响tPA溶栓后的患者预后。研究人员旨在分析急慢性高血糖与tPA治疗的患者临床预后的关系。方法:研究人员筛选2009年到2013年间“跟着指南走——卒中”中接受tPA治疗的来自1408个地方的58265名AIS患者。入院血糖>140 mg/dL,则定义为急性高血糖。血浆糖化血红蛋白(HbA1c)>6.5%,则定义为慢性高血糖